Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With CHF and Renal Impairment

NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)30 enrolled

Overview

The purpose of this study is to characterize the safety and tolerability of KW-3902IV and measure its effect on renal function.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Heart Failure, Congestive Renal Insufficiency

Interventions

KW-3902IVDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Stable congestive heart failure * Impaired renal function * Taking oral loop diuretic Exclusion Criteria: * Acutely decompensated (unstable) and end stage heart failure * Diuretics other than loop diuretics * Pregnant or nursing * Inability to follow instructions * Participation in another clinical trial within past 30 days

Locations (6)

Unnamed facility

San Diego, California, United States

Unnamed facility

Baltimore, Maryland, United States

Unnamed facility

Ayer, Massachusetts, United States

Unnamed facility

Boston, Massachusetts, United States

Outcomes

Primary Outcomes

Comparison of KW-3902IV alone or with loop diuretic on renal function.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.